Eli Lilly is offering 2.5-milligram and 5-milligram single-dose vials of Zepbound for $399 per month and $549 per month, respectively.
Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase access for patients without insurance coverage for the highly popular injection.
The lower price points will benefit patients who are willing to pay for Zepbound themselves and are enrolled in Medicare or employer-sponsored health plans that do not currently cover obesity treatments, said Patrik Jonsson, president of Eli Lilly diabetes and obesity, in an interview.for Zepbound. One program allows people with insurance coverage for Zepbound to pay as little as $25 out of pocket, while another allows those whose insurance does not cover the drug to pay as low as $550.
Patients with a valid prescription can purchase the single-dose vials from a new"self-pay pharmacy" section on the company's direct-to-consumer site, LillyDirect. Eli Lilly is partnering with a third-party digital pharmacy,People can also choose to purchase syringes and needles from Eli Lilly's website and will have access to materials on how to correctly administer Zepbound from a vial.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's Zepbound reduces type 2 diabetes risk, study showsEli Lilly announced results of a study in which weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among certain adults.
Read more »
Mounjaro/Zepbound Drastically Cuts Risk Of Type 2 Diabetes, Eli Lilly Report SuggestsArianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterEli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker. Lilly also hiked its forecast for the year well beyond Wall Street expectations as newer drugs like Zepbound built momentum.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterMounjaro sales more than tripled in the quarter to nearly $3.1 billion. Zepbound, which is made from the same molecule, brought in $1.2 billion two quarters after regulators approved the drug.
Read more »
Eli Lilly raises forecast after boost in Zepbound, Mounjaro salesEli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.
Read more »
Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarterli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.
Read more »